A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke

Ann N Y Acad Sci. 1995 Sep 15:765:328-9. doi: 10.1111/j.1749-6632.1995.tb16605.x.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Cerebrovascular Disorders / drug therapy*
  • Cerebrovascular Disorders / physiopathology
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Infusions, Intravenous
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use
  • Neuroprotective Agents / toxicity*
  • Piperazines / administration & dosage
  • Piperazines / therapeutic use
  • Piperazines / toxicity*
  • Placebos
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use
  • Pyrimidines / toxicity*

Substances

  • Neuroprotective Agents
  • Piperazines
  • Placebos
  • Pyrimidines
  • sipatrigine